CytomX Therapeutics, Inc.

CTMX · Nasdaq · SIC 2834: Pharmaceutical Preparations
207
SEC Filings

Business Summary

PART I Overview We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is des...

Next Earnings

Q2 FY2026 — expected 2026-08-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCTMXdiscussed_in_filing Cybersecurity
topic_mentionCTMXdiscussed_in_filing Cybersecurity
topic_mentionCTMXdiscussed_in_filing Healthcare & Bio
topic_mentionCTMXdiscussed_in_filing Platform & Ecosystem
topic_mentionCTMXdiscussed_in_filing Healthcare & Bio
topic_mentionCTMXdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001193125-26-107146EDGAR99K words
2025-03-062024-12-310000950170-25-034575EDGAR—
2024-03-112023-12-310000950170-24-029191EDGAR—
2023-03-272022-12-310000950170-23-009991EDGAR—
2022-03-012021-12-310000950170-22-002519EDGAR—
2021-02-242020-12-310001564590-21-008081EDGAR—
2020-02-272019-12-310001564590-20-007395EDGAR—
2019-02-272018-12-310001564590-19-004890EDGAR—
2018-03-072017-12-310001564590-18-004727EDGAR—
2017-03-022016-12-310001564590-17-003229EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269477EDGAR61K words
2025-08-072025-06-300000950170-25-104991EDGAR—
2025-05-122025-03-310000950170-25-068511EDGAR—
2024-11-072024-09-300000950170-24-123249EDGAR—
2024-08-082024-06-300000950170-24-093865EDGAR—
2024-05-082024-03-310000950170-24-055588EDGAR—
2023-11-072023-09-300000950170-23-060201EDGAR—
2023-08-082023-06-300000950170-23-039761EDGAR—
2023-05-092023-03-310000950170-23-019654EDGAR—
2022-11-082022-09-300000950170-22-023190EDGAR—
2022-08-042022-06-300000950170-22-014737EDGAR—
2022-05-052022-03-310000950170-22-007806EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001193125-26-115958EDGAR29K words
2026-03-160001193125-26-107152EDGAR—
2025-11-060001193125-25-269533EDGAR—
2025-08-130001193125-25-179463EDGAR—
2025-08-070000950170-25-105053EDGAR—
2025-06-130001193125-25-140739EDGAR—
2025-05-280001193125-25-129470EDGAR—
2025-05-130001193125-25-118805EDGAR—
2025-05-120001193125-25-117245EDGAR—
2025-03-060000950170-25-034585EDGAR—

207 total filings indexed. 175 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001501989
TickerCTMX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 6e5b0e6620a52f3d42a857968c24728265e409c4fd7c16cc14863deb0431272b
parent: 5b98d91a5189e7b3d50ef241349df4672a47f1db9e720399d3f475f97cbf7e12
content hash: a3e5876740cdc933303d2d901cc94bc87dce01eae368b3700e1e55062f670b49
signed: 2026-04-13T04:44:32.242Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf